Novo Nordisk Faces Forecast Cut Amid Obesity Drug Competition

Novo Nordisk, the famed maker of the obesity drug Wegovy, announced on Tuesday that its full-year sales and operating profit are expected to grow less than previously anticipated. This marks the second time the company has cut its 2025 forecast amidst challenging market conditions.

The Danish pharmaceutical giant is facing mounting pressure as it tries to hold its ground against U.S.-based competitor Eli Lilly in the booming obesity drug market. Investors have shown concern over Novo Nordisk's ability to remain competitive as its shares have seen a steep decline over the past year.

This development places additional scrutiny on Novo Nordisk's strategic positioning in the global market, as both companies vie for dominance with their respective weight-loss offerings.

(With inputs from agencies.)